Alaunos Therapeutics, Inc. (TCRT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Alaunos Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company currently focused on developing oral small molecules for obesity and metabolic disorders. The Company previously operated a clinical-stage oncology program (TCR-T cell therapy) which was strategically reprioritized and wound down in 2023. The Company is classified as a Smaller Reporting Company and a Non-Accelerated Filer.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $6 |
| Net Loss | $(1,159) | $(1,127) | $(3,283) | $(3,937) |
| EPS (Basic & Diluted) | $(0.55) | $(0.70) | $(1.84) | $(2.46) |
| Cash and Cash Equivalents | $1,938 (as of Sept 30, 2025) | |||
| Stockholders' Equity | $2,803 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(923,729) (as of Sept 30, 2025) | |||
| Working Capital | $1,764 (Current Assets $2,685 - Current Liabilities $921) |
Material Changes vs. Prior Period
- Revenue: Remained negligible ($0 for Q3 2025 vs. $0 for Q3 2024). YTD royalty revenue decreased to $2,000 from $6,000 in the prior year.
- Operating Expenses:
- R&D Expenses: Increased significantly to $469,000 in Q3 2025 from $143,000 in Q3 2024 (228% increase), driven by stock-based compensation, salaries, and consulting fees for the obesity program.
- G&A Expenses: Decreased to $718,000 in Q3 2025 from $1,007,000 in Q3 2024 (29% decrease), reflecting cost-cutting measures, reduced insurance costs, and downsized operations.
- Liquidity: Cash balances increased from $1,091,000 at year-end 2024 to $1,938,000 at Q3 2025, primarily due to financing activities including a registered direct offering and preferred stock sales.
- Capital Structure: Issued Series A-1 and Series A-2 Convertible Preferred Stock and common stock via a registered direct offering in 2025 to raise capital.
Guidance, Outlook, Risks, and Unusual Items
- Cash Runway: Management anticipates current cash resources ($1.9 million) will fund operations into the first quarter of 2026. The monthly burn rate is approximately $0.28 million.
- Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern due to the need for additional financing to fund operations beyond the current runway.
- Strategic Reprioritization: The Company is actively exploring strategic alternatives, including acquisitions, mergers, asset sales, or partnerships. Failure to consummate a transaction could lead to dissolution or liquidation.
- Nasdaq Compliance: The Company regained compliance with Nasdaq Listing Rule 5550(b)(1) (minimum $2.5 million stockholders' equity) in August 2025. As of September 30, 2025, equity stood at $2.82 million. However, ongoing losses pose a risk to future compliance.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, citing a material weakness in the internal control environment.
- Government Shutdown Risk: The filing highlights existential risks related to the U.S. government shutdown (effective Oct 1, 2025), which could delay SEC registration effectiveness, hinder capital raising, and stall strategic transactions.
- Legal/Contingencies: A dispute exists with MD Anderson regarding an R&D agreement; a demand for $192,000 was issued in November 2025, and the Company is negotiating a payment schedule.
Investor Verification Checklist
- Cash Runway Validation: Verify the accuracy of the $0.28 million monthly burn rate and the Q1 2026 runway projection given the current cash balance of $1.9 million.
- Capital Raise Status: Confirm the status of the $25 million equity line of credit and any follow-on offerings, particularly in light of the government shutdown risks to SEC effectiveness.
- Nasdaq Compliance: Monitor future quarterly reports to ensure stockholders' equity remains above the $2.5 million threshold required to avoid delisting.
- Internal Control Remediation: Review subsequent filings for updates on the remediation plan for the material weakness in internal controls over financial reporting.
- Strategic Transaction Progress: Assess any updates on the strategic review process (e.g., merger, asset sale) led by Cantor Fitzgerald & Co.
- MD Anderson Dispute: Track the resolution of the $192,000 payment dispute with MD Anderson to ensure no further litigation or financial impact.